HIV y la provisión de sangre: un análisis de la toma de decisiones en época de crisis

Leveton, Lauren B; Sox Junior, Harold C; Soto, Michael A.
Rev. argent. transfus ; 22(3): 155-67, jul.-sept. 1996.
Artículo en Español | LILACS | ID: lil-248850

Documentos relacionados

  1. Review of the standards of proof (of safety) for FDA regulated consumer products and how the generally recognized as safe criteria could be applied to cosmetics.
  2. A framework enabling LLMs into regulatory environment for transparency and trustworthiness and its application to drug labeling document.
  3. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
  4. Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration's 510(k) Pathway and Risk of Subsequent Recalls.
  5. 'A good day': FDA approves world's first RSV vaccine.
  6. Reducing tobacco-related harm: FDA's proposed product standard for smokeless tobacco.
  7. Eroding Judicial Deference to the FDA - Consequences for Public Health.
  8. A systematic assessment of key design and performance characteristics of drug exposure registries requested by the U.S. Food and Drug Administration.
  9. Bioequivalence for highly variable drugs: regulatory agreements, disagreements, and harmonization.
  10. FDA should stand firm on stem-cell treatments.